Evidence map›Paper›PMID 42337332›Full record

ArticleEuropean journal of human genetics : EJHG2026

BRCA1 c.68_69del as a founder variant in the Spanish Roma: prevalence and screening implications.

Ares Solanes-Cabús, Carmen Castillo-Manzano, Paula Rofes, Santiago Pérez-Marco, Judith Isach, Gisela Oñate, Iris Teruel, Marta Crous-Bou, Roser Lleuger-Pujol, Mónica Salinas and 8 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of human genetics : EJHG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Ares Solanes-Cabús *Hereditary Cancer Program, Catalan Institute of Oncology, Badalona, Girona and L'Hospitalet de Llobregat, Barcelona, Spain.
Carmen Castillo-Manzano *Hereditary Cancer Program, Catalan Institute of Oncology, Badalona, Girona and L'Hospitalet de Llobregat, Barcelona, Spain.ORCID http://orcid.org/0000-0003-4902-6247
Paula RofesHereditary Cancer Program, Catalan Institute of Oncology, Badalona, Girona and L'Hospitalet de Llobregat, Barcelona, Spain.
Santiago Pérez-MarcoInstitute of Evolutionary Biology (CSIC - UPF). Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
Judith IsachSant Roc Primary Care Center, Catalan Health Institute, Badalona, Spain.
Gisela OñateSant Roc Primary Care Center, Catalan Health Institute, Badalona, Spain.
Iris TeruelHereditary Cancer Program, Catalan Institute of Oncology, Badalona, Girona and L'Hospitalet de Llobregat, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5563-6562
Marta Crous-BouCancer Epidemiology Research Program, Catalan Institute of Oncology - Bellvitge Biomedical Research Center (ICO-IDIBELL), Barcelona, Spain.
Roser Lleuger-PujolHereditary Cancer Program, Catalan Institute of Oncology, Badalona, Girona and L'Hospitalet de Llobregat, Barcelona, Spain.
Mónica SalinasHereditary Cancer Program, Catalan Institute of Oncology, Badalona, Girona and L'Hospitalet de Llobregat, Barcelona, Spain.
Rafael de CidGenomes for Life-GCAT lab Group, Institut Germans Trias i Pujol (IGTP), Badalona, Spain.
Jesús Del ValleHereditary Cancer Program, Catalan Institute of Oncology, Badalona, Girona and L'Hospitalet de Llobregat, Barcelona, Spain.ORCID http://orcid.org/0000-0003-3607-7045
Lídia FeliubadalóHereditary Cancer Program, Catalan Institute of Oncology, Badalona, Girona and L'Hospitalet de Llobregat, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1736-0112
German PortelaSant Roc Primary Care Center, Catalan Health Institute, Badalona, Spain.
Matilde NavarroHereditary Cancer Program, Catalan Institute of Oncology, Badalona, Girona and L'Hospitalet de Llobregat, Barcelona, Spain.
Joan BrunetHereditary Cancer Program, Catalan Institute of Oncology, Badalona, Girona and L'Hospitalet de Llobregat, Barcelona, Spain.ORCID http://orcid.org/0000-0003-1945-3512
David ComasInstitute of Evolutionary Biology (CSIC - UPF). Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.ORCID http://orcid.org/0000-0002-5075-0956
Conxi LázaroHereditary Cancer Program, Catalan Institute of Oncology, Badalona, Girona and L'Hospitalet de Llobregat, Barcelona, Spain. clazaro@iconcologia.net.ORCID http://orcid.org/0000-0002-7198-5906

Funding

Generalitat de Catalunya (Government of Catalonia) 2021SGR01112Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III) PI23/00017; CGL2019-106485GB-I00 and PID2022-138755NB-I00
6 · The paper itself

Abstract

We hypothesized that the BRCA1 c.68_69del variant is highly prevalent among individuals with Roma ancestry from Spain due to a founder effect, as in the Ashkenazi Jewish population, where targeted screening has proven to be cost-effective. We conducted two cross-sectional prevalence studies in self-reported Roma adults from a community-based and a nationwide sample. To assess variant origin, we reconstructed haplotypes in carriers with Roma, Indian, Ashkenazi Jewish and European ancestry, and compared haplotype sharing and mutation-age estimates. BRCA1 c.68_69del variant was detected in 3.6% (16/440) of the community-based Roma sample and 0.8% (2/258) of the nationwide Roma sample. Roma carriers shared extended haplotypes (1.4-16.9 Mb) with carriers of presumed European and Ashkenazi Jewish ancestry, supporting a common founder, whereas minimal overlap (65 kb) with the Indian-ancestry carrier suggested an independent origin, despite the Roma population's Indian origin. Mutation-age estimates were 925 years ago in non-Roma carriers and 600 years ago in Roma carriers. Shared haplotypes support an Iberian founder later enriched in Roma, likely leading to a high prevalence of BRCA1 c.68_69del in Spanish Roma and supporting targeted genetic screening within this community.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.